| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
SARS-CoV-IN-3 targets SARS-CoV replication, likely through inhibition of the main protease (Mpro). As a hydroxyferroquine derivative, it also targets Plasmodium falciparum by interfering with heme detoxification. It also exhibits anti-HIV-1 activity, reducing cytopathic effects in MT-4 cells. The mechanism involves inhibition of viral protease activity and disruption of parasitic heme metabolism.
|
|---|---|
| ln Vitro |
In vitro, SARS-CoV-IN-3 (compound 4) inhibits Plasmodium falciparum development significantly more effectively than chloroquine (CQ) [1].
In vitro, SARS-CoV-IN-3 is antiviral against SARS-CoV with an EC50 of 3.6 microM in Vero cells. It inhibits P. falciparum 3D7 and W2 strains with IC50s of 11.7 and 20.4 nM, respectively, and IC90s of 29.19 and 56 nM, respectively. It is significantly more effective than chloroquine at preventing P. falciparum growth in vitro. In MT-4 cells, SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effects with an EC50 of 10 microM. It possesses antimalarial, anti-SARS-CoV, and anti-HIV-1 activities. |
| ln Vivo |
No specific in vivo activity data is available for SARS-CoV-IN-3. The compound is primarily studied in cell-based in vitro systems for antiviral, anti-HIV, and antiplasmodial activity.
|
| Enzyme Assay |
For in vitro antiviral assays: Infect Vero cells with SARS-CoV at an appropriate MOI. Treat cells with SARS-CoV-IN-3 at concentrations ranging from 0.1-100 microM. Incubate for 48-72 hours. Measure viral replication by plaque assay or qRT-PCR. Calculate EC50 values. For anti-HIV assays: Infect MT-4 cells with HIV-1. Treat with SARS-CoV-IN-3 at varying concentrations. Assess inhibition of HIV-1-induced cytopathic effects by MTT or XTT assay after 5-7 days. Calculate EC50. For antiplasmodial assays: Culture P. falciparum 3D7 and W2 strains in human red blood cells. Treat with SARS-CoV-IN-3 (1-1000 nM) for 48-72 hours. Measure parasite growth inhibition by HRP2 ELISA or 3H-hypoxanthine incorporation. Calculate IC50 and IC90 values.
|
| Animal Protocol |
No specific in vivo protocol exists. The compound may be studied in mouse malaria models with intraperitoneal administration, or in SARS-CoV animal models with intranasal or intraperitoneal administration. These protocols require validation.
|
| ADME/Pharmacokinetics |
The compound is soluble in DMSO at 7.81 mg/mL (16.63 mM). For in vivo formulation, it can be prepared in DMSO: Tween80: Saline = 10:5:85 (IP/IV/IM/SC) or in DMSO:PEG300:Tween80:Saline = 10:40:5:45. As a powder, store at -20degC for up to 3 years.
|
| Toxicity/Toxicokinetics |
Resistance to SARS-CoV-IN-3 is likely due to mutations in the SARS-CoV-2 main protease (Mpro) gene affecting drug binding. Common mutations such as V3L, I126V, or L50F in Mpro can lead to decreased drug efficacy. Cross-resistance with other Mpro inhibitors targeting similar binding sites is possible. Regular sequencing of the Mpro gene is recommended to track resistance development. The compound is for research use only.
|
| References | |
| Additional Infomation |
SARS-CoV-IN-3 is a research-grade compound for laboratory use only, not for human therapeutic applications. It acts as a potent coronavirus Mpro inhibitor and is used for replication inhibition research. It can be paired with polymerase, protease, or host-factor inhibitors to enhance multi-target suppression. It serves as a reference scaffold in coronavirus inhibitor optimization. The compound should be stored at -20degC protected from light. It is soluble in DMSO at 10 mM; protect from light during handling. Avoid prolonged handling at room temperature. Use aliquots to maintain reproducibility. No clinical trials or approved status exist.
|
| Molecular Formula |
C??H??CLFEN?O
|
|---|---|
| Molecular Weight |
469.74
|
| CAS # |
888958-27-8
|
| Appearance |
Light yellow to yellow solid powder
|
| SMILES |
C(C12=C3C4=C5[C-]1(CNC1=CC=NC6C=C(Cl)C=CC1=6)[Fe+2]16782354C2=C1C6=C7[C-]82)N(CC)CCO
|
| Synonyms |
SARSCoVIN3; SARS CoV IN 3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.81 mg/mL (~16.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1288 mL | 10.6442 mL | 21.2884 mL | |
| 5 mM | 0.4258 mL | 2.1288 mL | 4.2577 mL | |
| 10 mM | 0.2129 mL | 1.0644 mL | 2.1288 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
